SCHEMBL4675460

SCHEMBL4675460

O=C(C=C(O)c1nc[nH]n1)c1cc(Oc2cccc(Cl)c2)co1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
ABL1 P00519 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
XDH P47989 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
HAO1 Q9UJM8 1/20 0.33
CYP3A4 P08684 1/20 0.33
GRM5 P41594 1/20 0.32
NAAA Q02083 1/20 0.32
FKBP1A P62942 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
CDK8 P49336 1/20 0.32
NR4A2 P43354 1/20 0.32
KDM4E B2RXH2 1/20 0.32
KLKB1 P03952 1/20 0.32
PPARG P37231 1/20 0.32
FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673353 0.89 ALDH1A1 (0.34) LMNACYP3A4KDM4E
SCHEMBL4675663 0.89 CDH1 (0.38) LMNAKDM4EPPARGCHEK2
SCHEMBL4675372 0.88 LMNA (0.38) LMNAHAO1KDM4E
SCHEMBL4676486 0.85 KDM4E (0.39) CDK8NR4A2KDM4EPPARG
SCHEMBL4675073 0.84 RAB9A (0.37) ABL1RXRARXRBCYP3A4KDM4E
SCHEMBL4677855 0.84 ALDH1A1 (0.43) LMNAABL1RXRARXRBRXRG
SCHEMBL4674635 0.83 LMNA (0.36) LMNAABL1RXRARXRBRXRG
SCHEMBL4676171 0.82 PARP10 (0.33) CYP3A4
SCHEMBL4671052 0.82 NR4A2 (0.33) LMNACYP3A4NR4A2KDM4ECHEK2
SCHEMBL4673040 0.82 HCAR2 (0.40) LMNARXRARXRBRXRGNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LMNA 659/4885ABL1 494/4885RXRA 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.